丹参川芎嗪注射液联合缬沙坦治疗早期糖尿病肾病的临床观察

Clinical observation of the effectiveness of salvia ligustrazine combined with valsartan in treating diabetic nephropathy at early stage

目的探讨丹参川芎嗪注射液联合缬沙坦治疗早期糖尿病肾病临床疗效。方法选择糖尿病肾病Ⅲ期78例患者,随机分观察组39例和对照组39例。对照组给缬沙坦80 mg,1次/d,共4周。观察组在应用缬沙坦的基础上,加用丹参川芎嗪注射液10 mL+生理盐水250 mL静滴,1次/d,共4周。结果观察组与对照组治疗后血肌酐24 h尿蛋白定量、糖化血红蛋白、收缩压、舒张压,治疗前后比较差异有统计学意义(P<0.05),组间差异亦有统计学意义(P<0.05)。结论丹参川芎嗪注射液联合缬沙坦治疗早期糖尿病肾病疗效优于对照组,且无明显不良反应。

【Objective】 To investigate the clinical effectiveness of salvia ligustrazine combined with valsartan in treating diabetic nephropathy of early stage.【Methods】 78 cases with diabetic nephropathy stage Ⅲ were randomly divided into two groups,with 39 cases each in the experimental group and control group.Valsartan of 80 mg were administrated once a day for 4 weeks in control group.And for experimental group in addition to the valsartan treatment,salvia ligustrazine of 10ml and NS 250 mL were injected by intravenous drip infusion also for 4 weeks.【Result】 Levels of serum creatinine,quantification of proteinuria in 24 hour,glycosylated hemoglobin,systolic pressure,diastolic pressure were all different significantly after the treatments and there was also a significant difference between the two groups.【Conclusion】 Compared to the valsartan alone,salvia ligustrazine combined with valsartan is more effective and with less side effects in the treatment of diabetic nephropathy at early stage.